RAFFLES MEDICAL GROUP LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.03 SGD | +0.98% |
|
0.00% | -4.63% |
| Sales 2024 * | 71Cr 52Cr 4.37TCr | Sales 2025 * | 76Cr 56Cr 4.7TCr | Capitalization | 191.3Cr 141.5Cr 12TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 7.4Cr 5.47Cr 456.13Cr | Net income 2025 * | 8.4Cr 6.21Cr 517.77Cr | EV / Sales 2024 * | 2.31 x |
| Net cash position 2024 * | 27Cr 20Cr 1.67TCr | Net cash position 2025 * | 33Cr 25Cr 2.06TCr | EV / Sales 2025 * | 2.07 x |
| P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
23.1
x | Employees | 2,892 |
| Yield 2024 * |
2.23% | Yield 2025 * |
2.61% | Free-Float | 42.35% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.98% | ||
| Current month | +3.00% | ||
| 1 month | +1.98% | ||
| 3 months | +0.98% | ||
| 6 months | -2.83% | ||
| Current year | -4.63% |
1 week
1.02
1.04
1 month
1.001.04
Current year
0.991.10
1 year
0.991.42
3 years
0.991.58
5 years
0.731.58
10 years
0.731.68
| Managers | Title | Age | Since |
|---|---|---|---|
Alfred Loh
FOU | Founder | - | 01/76/01 |
Won Lein Ng
DFI | Director of Finance/CFO | 58 | 02/20/02 |
Fook Meng Wong
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Choon Yong Loo
FOU | Founder | 74 | 01/76/01 |
Qing Hui Lu
BRD | Director/Board Member | 42 | 20/18/20 |
Soo Nan Tan
BRD | Director/Board Member | 75 | 28/00/28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 746 M€ | -.--% | - | |
| 0.00% | 34 M€ | +3.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 1.03 | +0.98% | 1,711,500 |
| 28/24/28 | 1.02 | -0.97% | 717,100 |
| 27/24/27 | 1.03 | 0.00% | 919,400 |
| 24/24/24 | 1.03 | -0.96% | 993,400 |
| 23/24/23 | 1.04 | +0.97% | 558,900 |
Delayed Quote Singapore S.E., May 29, 2024 at 02:39 pm IST
More quotes
Raffles Medical Group Ltd is a Singapore-based integrated private healthcare provider. The principal activities of the Company are those relating to the operation of medical clinics, other general medical services, and investment holdings. The Companyâs segments include Healthcare Services, Hospital Services, and Investment Holdings. The Healthcare Services segment is engaged in the operations of medical clinics and other general medical services; provision of health insurance, trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management and consultancy services. The Hospital Services segment is engaged in the provision of specialized medical services and operation of hospital and business of medical laboratory and imaging center. The Investment Holdings segment is engaged in investment holding and those relating to investment properties. It operates medical facilities in about 14 cities in Singapore, China, Japan, Vietnam, and Cambodia.
Calendar
29/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
1.03
SGD
Average target price
1.135
SGD
Spread / Average Target
+10.19%
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- BSL Stock
